The U.S. Food and Drug Administration on Friday approved Roche's under-the-skin injection to treat patients with multiple ...

Levels of antibodies targeting the Epstein-Barr virus are not associated with disease activity among multiple sclerosis ...

Discover how wearable technology is changing the understanding of MS through real-time brain function tracking and analysis ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...

DelveInsight's Chronic Progressive Multiple Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, chronic progressive multiple sclerosis emerging ...

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 millionRaises full year 2025 global revenue ...

A study using wearable scanning technology has revealed how brain function differs in people with multiple sclerosis (MS). It ...

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of ...

Discover the pros and cons of maintaining an MS symptom diary. Learn how it can aid in identifying relapses and triggers, improve doctor communication, but also cause stress for some.

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

Having a higher BMI at diagnosis is tied to faster disability progression in people with multiple sclerosis, according to a ...